Gilead, Foresite Take Pardes Biosciences Public In $250M SPAC Deal

• Pardes Biosciences Inc, an early-stage biopharmaceutical company, and FS Development Corp. II (NASDAQ: FSII), a Foresite Capital sponsored SPAC, entered into a definitive merger agreement.

• Pardes Biosciences was founded at the beginning of 2020 by Uri Lopatin, a former Gilead executive who co-founded and served as CMO of Assembly Biosciences.

• Despite the thin online presence, Foresite is giving Pardes the $175 million they raised for the SPAC, plus another $75 million in private funding from Gilead Sciences Inc (NASDAQ: GILD), RA Capital Management, and Frazier Life Sciences.

• The company anticipates initiating clinical trials later this year and plans to study PBI-0451 for prophylaxis and treatment of SARS-CoV-2 infections.

• The U.S. recently announced a .2 billion program to accelerate the development of antivirals for future pandemics. And Pardes' lead program, PBI-0451, is an oral antiviral drug candidate designed to inhibit an essential viral protein causing COVID-19.

• Price Action: FSII shares are up 0.62% at $9.94 during the market session on the last check Tuesday.

See more from Benzinga

• Click here for options trades from Benzinga

• Gilead's Yescarta Touts Positive Data In Second-Line Large B-Cell Lymphoma Patients

• Gilead's Kite Pharma Collaborates With Shoreline Biosciences For Cell Therapies For Cancer Settings

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.